Trials / Withdrawn
WithdrawnNCT04530877
Exclusive Enteral Nutrition vs. Infliximab in Chinese CD Patients
Comparative Effectiveness of Exclusive Enteral Nutrition and Infliximab in Chinese Children With Active Crohn's Disease
- Status
- Withdrawn
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Children's Hospital of Fudan University · Academic / Other
- Sex
- All
- Age
- 1 Year – 18 Years
- Healthy volunteers
- Accepted
Summary
prospectively compared Exclusive Enteral Nutrition with Infliximab in the clinical outcomes, mucosal healing, nutrition improvements, adverse effects and gastrointestinal microbiota changes on Chinese Children With active Crohn's Disease
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Infliximab | Infliximab, a monoclonal antibody-targeting tumor necrosis factor (TNF), is one of the primary treatment strategies for active pediatric CD |
| DIETARY_SUPPLEMENT | Exclusive Enteral Nutrition | the administration of a liquid formula diet with the exclusion of all other regular food for 6-8 weeks， the volume was determined according to the energy needs of the patient. All patients received high energy intakes (\>110%-120% of the average requirement). |
Timeline
- Start date
- 2022-10-01
- Primary completion
- 2024-09-30
- Completion
- 2024-09-30
- First posted
- 2020-08-28
- Last updated
- 2022-08-09
Source: ClinicalTrials.gov record NCT04530877. Inclusion in this directory is not an endorsement.